AS/Spondyloarthritis

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute…

Psoriatic arthritis (PsA) commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research…

Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult.  Promptly distinguishing…

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axial spondyloarthritis (ax-Spa), whether they are diagnosed with…

Delay in the diagnosis of axial spondyloarthritis (axSpA) has been a huge challenge and is associated with poor outcomes. Poster # 0359 by Garrido-Cumbrera et al. set out to map out patients'…

Who wouldn't like to predict the future?  In Abstract 0380, Dr. Nikiphorou et al studied sick leave in relationship to axSpA. Patients from the DESIR cohort with work-related data and up to 5…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and…

As patients with rheumatic disease become important partners in raising awareness and management of their conditions, their valuable contributions in research are reflected in the poster sessions on…